ALERS Stock Overview
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Eurobio Scientific Société anonyme Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €14.80 |
| 52 Week High | €18.10 |
| 52 Week Low | €12.20 |
| Beta | -0.37 |
| 1 Month Change | -6.21% |
| 3 Month Change | -7.62% |
| 1 Year Change | -9.20% |
| 3 Year Change | -31.86% |
| 5 Year Change | 362.50% |
| Change since IPO | -85.14% |
Recent News & Updates
Recent updates
Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Jul 29
Estimating The Fair Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Apr 07Is Now The Time To Put Eurobio Scientific Société anonyme (EPA:ALERS) On Your Watchlist?
Mar 08Calculating The Intrinsic Value Of Eurobio Scientific Société anonyme (EPA:ALERS)
Jan 03Improved Earnings Required Before Eurobio Scientific Société anonyme (EPA:ALERS) Stock's 28% Jump Looks Justified
Dec 13Should You Be Adding Eurobio Scientific Société anonyme (EPA:ALERS) To Your Watchlist Today?
Nov 20Eurobio Scientific Société anonyme's (EPA:ALERS) Earnings Are Of Questionable Quality
May 12Shareholder Returns
| ALERS | FR Biotechs | FR Market | |
|---|---|---|---|
| 7D | -2.4% | -1.4% | -0.1% |
| 1Y | -9.2% | -13.0% | 1.3% |
Return vs Industry: ALERS exceeded the French Biotechs industry which returned -13% over the past year.
Return vs Market: ALERS underperformed the French Market which returned 1.3% over the past year.
Price Volatility
| ALERS volatility | |
|---|---|
| ALERS Average Weekly Movement | 4.0% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.4% |
| 10% most volatile stocks in FR Market | 9.5% |
| 10% least volatile stocks in FR Market | 2.3% |
Stable Share Price: ALERS has not had significant price volatility in the past 3 months.
Volatility Over Time: ALERS's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1997 | 304 | Denis Fortier | www.eurobio-scientific.com |
Eurobio Scientific Société anonyme engages in the design, development, and commercialization of in vitro diagnostics products in the areas of transplantation, immunology, infectious diseases, life-science, and cancer. It commercializes media for the transportation and preservation of cornea grafts, as well as a device to facilitate the corresponding surgery; AlloMap, a molecular test for the surveillance of heart-transplant patients; cell culture media, molecular biology reagents, and proprietary antibodies; TQS (Tetanus Quick Stick) for the evaluation of patients’ immune status against tetanus; and EBX molecular biology family, which includes a range of tests for identifying various pathogens responsible for infectious diseases and assessing the magnitude of the infection. The company also develops other diagnostic products using molecular biology.
Eurobio Scientific Société anonyme Fundamentals Summary
| ALERS fundamental statistics | |
|---|---|
| Market cap | €151.32m |
| Earnings (TTM) | €4.80m |
| Revenue (TTM) | €130.60m |
31.5x
P/E Ratio1.2x
P/S RatioIs ALERS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALERS income statement (TTM) | |
|---|---|
| Revenue | €130.60m |
| Cost of Revenue | €68.80m |
| Gross Profit | €61.80m |
| Other Expenses | €57.00m |
| Earnings | €4.80m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 47.32% |
| Net Profit Margin | 3.68% |
| Debt/Equity Ratio | 60.8% |
How did ALERS perform over the long term?
See historical performance and comparison